{
  "source": "PA-Med-Nec-Emverm.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2114-10\nProgram Prior Authorization – Medical Necessity\nMedication Albenza (albendazole), Emverm (mebendazole)\nP&T Approval Date 11/2016, 3/2017, 6/2017, 6/2018, 5/2019, 4/2020, 5/2021, 5/2022,\n6/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nAlbenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions\ncaused by larval forms of the pork tapeworm, Taenia solium. Albenza is also indicated for the\ntreatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of\nthe dog tapeworm, Echinococcus granulosus.\nEmverm is indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura\n(whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common\nhookworm) and Necator americanus (American hookworm) in single or mixed infections.\nCDC guidelines recommend use in several other parasitic infections.\n2. Coverage Criteriaa:\nA. Enterobius vermicularis (pinworm)\n1. Albenza or Emverm will be approved based on both of the following:\na. Diagnosis of Enterobius vermicularis (pinworm)\n-AND-\nb. History of failure, contraindication or intolerance to over-the-counter pyrantel\npamoate\nAuthorization will be issued for one month.\nB. Taenia solium and Taenia saginata (Taeniasis or Cysticercosis/Neurocysticercosis)\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Taeniasis or Cysticercosis/Neurocysticercosis\nAuthorization will be issued for six months.\nC. Echinococcosis (Tapeworm)\n1. Albenza or Emverm will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n1\na. Diagnosis of Hydatid Disease [Echinococcosis (Tapeworm)]\nAuthorization will be issued for six months.\nD. Ancylostoma/Necatoriasis (Hookworm)\n1. Emverm will be approved based on the following criterion:\na. Diagnosis of Ancylostoma/Necatoriasis (Hookworm)\nAuthorization will be issued for one ",
    "ix months.\nD. Ancylostoma/Necatoriasis (Hookworm)\n1. Emverm will be approved based on the following criterion:\na. Diagnosis of Ancylostoma/Necatoriasis (Hookworm)\nAuthorization will be issued for one month.\n2. Albenza will be approved based on the following criterion:\na. Diagnosis of Ancylostoma/Necatoriasis (Hookworm)\nAuthorization will be issued for six months.\nE. Ascariasis (Roundworm)\n1. Albenza or Emverm will be approved based on the following criterion:\na. Diagnosis of Ascariasis (Roundworm)\nAuthorization will be issued for one month.\nF. Toxocariasis (Roundworm)\n1. Albenza or Emverm will be approved based on the following criterion:\na. Diagnosis of Toxocariasis (Roundworm)\nAuthorization will be issued for one month.\nG. Trichinellosis\n1. Albenza or Emverm will be approved based on the following criterion:\na. Diagnosis of Trichinellosis\nAuthorization will be issued for one month.\nH. Trichuriasis (Whipworm)\n1. Albenza or Emverm will be approved based on the following criterion:\na. Diagnosis of Trichuriasis (Whipworm)\nAuthorization will be issued for one month.\n© 2024 UnitedHealthcare Services, Inc.\n2\nI. Capillariasis\n1. Albenza or Emverm will be approved based on the following criterion:\na. Diagnosis of Capillariasis\nAuthorization will be issued for one month.\nJ. Baylisascaris\n1. Albenza or Emverm will be approved based on the following criterion:\na. Diagnosis of Baylisascaris\nAuthorization will be issued for one month.\nK. Clonorchiasis (Liver flukes)\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Clonorchiasis\nAuthorization will be issued for one month.\nL. Gnathostomiasis\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Gnathostomiasis\nAuthorization will be issued for one month.\nM. Strongyloidiasis\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Strongyloidiasis\nAuthorization will be issued for one month.\nN. Loiasis\n1. Albenza will be approved based on the following criteri",
    "za will be approved based on the following criterion:\na. Diagnosis of Strongyloidiasis\nAuthorization will be issued for one month.\nN. Loiasis\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Loiasis\nAuthorization will be issued for one month.\n© 2024 UnitedHealthcare Services, Inc.\n3\nO. Opisthorchiasis\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Opisthorchiasis\nAuthorization will be issued for one month.\nP. Anisakiasis\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Anisakiasis\nAuthorization will be issued for one month.\nQ. Microsporidiosis\n1. Albenza will be approved based on the following criterion:\na. Diagnosis of Microsporidiosis not caused by Enterocytozoon bieneusi or Vittaforma\ncorneae.\nAuthorization will be issued for twelve months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. CDC treatment guidelines. http://www.cdc.gov./parasites. Accessed July 2024.\n2. Albendazole [package insert]. Piscataway, NJ: Camber Pharmaceuticals, Inc; November\n2022.\n3. Emverm [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; August 2021.\n4. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and\nAdolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-\nand-adolescent-opportunistic-infections/microsporidiosis. Accessed July 2024.\n© 2024 UnitedHealthcare Services, Inc.\n4\nProgram Prior Authori",
    "alinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-\nand-adolescent-opportunistic-infections/microsporidiosis. Accessed July 2024.\n© 2024 UnitedHealthcare Services, Inc.\n4\nProgram Prior Authorization – Medical Necessity – Anthelmintics\nChange Control\n11/2016 New program.\n3/2017 Updated background. Incorporated CDC and FDA labeled indications.\nUpdated authorization time based on CDC and FDA recommendations.\n6/2017 Added Albenza as an approvable drug for Mansonella perstans\n(Filariasis). State mandate reference language updated.\n6/2018 Annual review. References updated.\n5/2019 Annual review. Added Albenza for Clonorchiasis, Gnathostomiasis,\nStrongyloidiasis per CDC treatment guidelines. Removed Albenza for\nMansonella perstans per CDC treatment guidelines. Updated\nreferences.\n4/2020 Annual review. Added Albenza for Loa loa, Opisthorchis per CDC\nguidelines. Removed Emverm and Vermox for Mansonella perstans.\n5/2021 Annual review. Removed Vermox from program due to product\ndiscontinuation. Updated references.\n5/2022 Annual review. Changed Ancylostoma/Necatoriasis authorization to six\nmonths per CDC recommendation for Albenza. Formatting changes.\nUpdated references.\n6/2023 Annual review. Added Albenza for Anisakiasis and Microsporidiosis\nper CDC and NIH guidelines, respectively. Updated references.\n8/2024 Annual review. Clarified spelling of Opisthorchiasis.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}